Search

Your search keyword '"Longo J"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Longo J" Remove constraint Author: "Longo J" Publisher bmj Remove constraint Publisher: bmj
25 results on '"Longo J"'

Search Results

3. FRI0619-HPR Joint Prostheses and Biologic Therapies in a Rheumatologic Clinic

5. AB0396 Infliximab and Adalimumab Levels and Antidrug Antibodies Detection in Patients with Rheumatoid Arthritis (RA): an Interlaboratory Comparison Using A Commercial ELISA Assay

6. SAT0340 Infliximab Levels and Anti-Infliximab Antibodies Comparison between Two Comercial ELISA Versions in Patients with Ankylosing Spondylitis

7. THU0250 Predictive Value of Doppler Ultrasound-Detected Synovitis in Relation to Successful Tapering of Biology Therapy in Patients with Rheumatoid Arthritis

8. SAT0318 Antisynthetase Syndrome: Clinical and Serological Characteristics at Disease Onset: Table 1.

9. AB0398 Relation between Serum Infliximab Levels and Changes of Rheumatoid Factor and Antibodies to Citrullinated Peptides Levels in Patients with Rheumatoid Arthritis

10. AB0434 Relation of Subclinical Ultrasound Detected Synovitis and Peripheral B-Cell Counts in Rheumatoid Arthritis Patients Treated with Rituximab

11. AB0027 B-Cell Activating Factor (BAFF) Binding Receptors (BBR) on B Cells: Characterization in Patients with Rheumatoid Arthritis (RA) Receiving Biological Therapies: Anti-TNF, Anti-Il6r and Anti-Ctla4: A Longitudinal Study

12. THU0585-HPR Impact on the Therapeutic Response to Anti-Tumor Necrosis Factor (ANTI-TNF) Agents of the Thickness of the Subcutaneous Tissue (SBC) in the Site of Injection Measured by Ultrasound

13. AB0026 B-Cell Profile in RA Patients Treated with Two Different Biological Therapeutic Targets: Anti-TNF and Anti-Il6r. A Cross-Sectional Study

14. THU0187 Does Ultrasound-Scored Synovitis Depend on the Pharmacokinetics of Subcutaneous Anti-TNF Agents in Patients with Rheumatoid Arthritis?: Table 1.

15. AB0041 B-cell activating factor (BAFF) binding receptors (BBR) on B cells: characterization in patients with rheumatoid arthritis (RA) receiving anti-TNF-alpha agent infliximab (IFX)

16. THU0215 Establishing Cut-Off of Infliximab and Anti-Infliximab Antibody Levels Using a Commercial Elisa in Patients with Rheumatoid Arthritis

17. SAT0228 Study of the disease activity and refractoriness to the treatment in a large spanish multicentric cohort of patients with systemic lupus erythematosus

18. THU0180 Prevalence and clinical significance of severe infection in patients with systemic lupus erythematosus: Preliminary data from relesser (registry of lupus of the spanish society of rheumatology)

19. SAT0135 Modified antitnf dose patterns in clinical practice: Achieving clinical control with minimum effective dosages

20. SAT0209 Characterization of pure membranous lupus nephritis: A cohort of 134 patients

21. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

24. Genetic variation in the nuclear factor kappaB pathway in relation to susceptibility to rheumatoid arthritis.

25. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.

Catalog

Books, media, physical & digital resources